Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;26(23):5943-5947.
doi: 10.1111/jcmm.17605. Epub 2022 Nov 11.

Screening by high-throughput sequencing for pathogenic variants in cystic fibrosis: Benefit of introducing personalized therapies

Ana Cristina Vieira de Melo  1 , Karla Simone Costa de Souza  2 , Heglayne Pereira Vital da Silva  2 , Jussara Melo de Cerqueira Maia  1 , Vera Maria Dantas  1 , João Felipe Bezerra  3 , Adriana Augusto de Rezende  2
Affiliations

Screening by high-throughput sequencing for pathogenic variants in cystic fibrosis: Benefit of introducing personalized therapies

Ana Cristina Vieira de Melo et al. J Cell Mol Med. 2022 Dec.

Abstract

This short report documented cystic fibrosis transmembrane conductance regulator (CFTR) variants in 37 patients with cystic fibrosis (CF) in the Rio Grande do Norte region of Northeast Brazil. The high-throughput sequencing technology (HTS) genetic testing provided a definitive molecular diagnosis in 31 patients (83.8%). Among them, 25 patients' carriers of the c.1521_1523delCTT variant, categorized as a class 2 mutation, can be currently treated with CFTR modulator drugs. Five children aged 2-5 years could benefit from double lumacaftor/ivacaftor therapy, and 20 patients aged >6 years could be treated with the triple-combination elexacaftor/tezacaftor/ivacaftor therapy. Thus, the identification of pathogenic variants associated with the development of this disease allows for the introduction of therapy with CFTR modulators that favour better patient management.

Keywords: CFTR gene; CFTR modulators therapies; cystic fibrosis; high-throughput sequencing; variants.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest to disclose.

References

    1. Pereira S, Ribeiro J, Ribeiro A, Bertuzzo C, Marson F. Novel, rare and common pathogenic variants in the CFTR gene screened by high‐throughput sequencing technology and predicted by in silico tools. Sci Rep. 2019;9(1):6234. doi:10.1038/s41598-019-42404-6 - DOI - PMC - PubMed
    1. da Silva Filho LVRF, Marostica P, Athanazio R, et al. Brazilian cystic fibrosis patient registry contributors team. extensive CFTR sequencing through NGS in brazilian individuals with cystic fibrosis: unravelling regional discrepancies in the country. J Cyst Fibros. 2021;20(3):473‐484. doi:10.1016/j.jcf.2020.08.007 - DOI - PubMed
    1. Clinical and Functional Translation of CFTR. Accessed May 06, 2022. http://cftr2.org/
    1. Dunnen J, Dalgleish R, Maglott D, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;7(3):564‐569. doi:10.1002/humu.22981 - DOI - PubMed
    1. Marson F, Bertuzzo C, Ribeiro J. Classification of CFTR mutation classes. Lancet. 2016;4:37‐38. doi:10.1016/S2213-2600(16)30188-6 - DOI - PubMed

Publication types

MeSH terms

Substances